Securities code: 002107 securities abbreviation: Shandong Wohua Pharmaceutical Co.Ltd(002107) Announcement No.: 2022-013 Shandong Wohua Pharmaceutical Co.Ltd(002107) summary of 2021 annual report I. important tips
The summary of this annual report comes from the full text of the annual report. In order to fully understand the company’s operating results, financial status and future development plan, investors should carefully read the full text of the annual report in the media designated by the CSRC.
All directors of the company personally attended the meeting of the board of directors to consider this annual report
Tips on non-standard audit opinions
□ applicable √ not applicable
Profit distribution plan for common shares or plan for conversion of reserve fund into share capital in the reporting period considered by the board of directors
√ applicable □ not applicable
Whether to increase share capital with accumulation fund
□ yes √ no
The company’s profit distribution plan for common shares reviewed and approved by the board of directors is: take 577209600 shares as the base, distribute cash dividends of 2.60 yuan (including tax) to all shareholders for every 10 shares, send bonus shares of 0 shares (including tax), and do not convert accumulation fund into share capital.
Profit distribution plan for preferred shares in the reporting period adopted by the board of directors
□ applicable √ not applicable
2、 Basic information of the company 1. Company profile
Stock abbreviation Shandong Wohua Pharmaceutical Co.Ltd(002107) stock code 002107
Stock exchange Shenzhen Stock Exchange
Contact person and contact information secretary of the board of directors securities affairs representative
Name: Zhao Caixia
Office address: No. 3517, Liyuan street, Weifang High tech Industrial Development Zone, Shandong Province
Fax 0536-8553373
Tel: 0536-8553373
E-mail [email protected].
2. Introduction to main business or products during the reporting period
(I) main business of the company
The predecessor of the company can be traced back to wanhetang pharmaceutical village during the Qianlong period of the Qing Dynasty. It is a Chinese patent medicine enterprise with a history of more than 200 years, integrating R & D, production and sales.
Through independent research and development, joint research and development, introduction and acquisition, the company has built a wohua ® Xinkeshu tablet, Gushukang capsule / granule, Hedan tablet / capsule and Naoxueshu oral liquid are strong exclusive product lines supported by four exclusive medical insurance products. With the strong development of the “four exclusive medical insurance pillar products”, the company has driven the sales of other exclusive products and generic drugs from point to area, resource sharing and synergy, so as to realize the long-term sustainable and high-speed growth of sales revenue.
Shandong Wohua Pharmaceutical Co.Ltd(002107) at present, there are 162 drug approval numbers, including 15 exclusive products, 93 products have entered the national catalogue of drugs for basic medical insurance, industrial injury insurance and maternity insurance (2021 version), and 43 products have entered the national catalogue of essential drugs (2018 version). Among the exclusive products, wohua ® Xinkeshu tablet, Gushukang capsule / granule, Hedan tablet / capsule and Naoxueshu oral liquid have strong market foundation, significant curative effect, safe use and great development potential. Their brand influence in the field of subdivided treatment has been continuously improved. They are the “four exclusive medical insurance pillar products” created by the company by concentrating advantageous resources, focusing on the subdivided market. Driven by the “four exclusive medical insurance pillar products”, the company’s other exclusive products and generic medicine resources are shared and synergistic, realizing the common growth of the whole product line. On the one hand, the formation of a strong exclusive product line stems from the company’s independent and joint research and development, continuous research on the modernization of traditional Chinese medicine, research and development of new drugs and secondary development of existing products, and constantly improve the level of product technology and quality control; On the other hand, relying on capital operation experience and resources, the company introduced exclusive products through enterprise M & A, such as Gushukang capsule / granule, Hedan tablet / capsule and other exclusive medical insurance products, which were successfully introduced through the acquisition of Liaoning wohua Kangchen and Nanchang Jishun. In the future, the company will focus on the main business of Chinese patent medicine production and sales, rely on the existing rich exclusive product line, deeply tap the potential, and realize the growth pattern of “four exclusive medical insurance pillar products” and coordinated development of other varieties. Continue to cooperate with scientific research institutions, make good use of the national policies conducive to the R & D of new traditional Chinese medicine, such as encouraging the approval of new drugs, encouraging the transformation of classic prescriptions and hospital preparations to new drugs, and encouraging the secondary development of products, strengthen the cooperative R & D of new products, and constantly enrich the exclusive product line.
The company has established modern production bases in Weifang, Dandong and Nanchang that meet the national GMP standards. Weifang base has 11 dosage forms and 106 products, 2 pretreatment extraction workshops and 1 comprehensive preparation workshop, and 4 intelligent production lines such as tablets / hard capsules, granules, pills and oral liquid preparations. Dandong base now produces 3 dosage forms and 37 products, has 2 extraction workshops and 2 preparation production workshops, and has 3 pretreatment extraction production lines and 3 oral solid preparation production lines. Nanchang base now produces 3 dosage forms and 19 products, and has 3 production lines of tablets, capsules and granules. Each production base shall unify the procurement platform, share technology and talents, and realize resource sharing and synergy in an all-round way. At the same time, continuously optimize process technology, continuously upgrade and update equipment, improve lean production and intelligent level, and improve production efficiency. During the reporting period, the company completed the construction of MES system in the primary stage, further improving the production intelligent management level.
Relying on many exclusive products with rich categories and unique competitive advantages, the company has built a rare full terminal and full mode marketing system in China. After years of continuous investment and operation, the company has established quite complete and efficient budget system, professional clinical academic promotion mode, terminal intermediary service provider mode and OTC retail mode, covering all kinds of terminals such as grade hospitals, retail pharmacies and grass-roots medical institutions. Through various academic and promotion activities, the company’s marketing system continues to carry out clinical treatment and medication research, efficiently disseminate academic achievements, improve brand influence and reputation, and continuously improve the market coverage and share of the company’s products. At the beginning of 2020, the company deeply analyzed the changing trend of the industry, combined with the new situation of policy, epidemic impact and market competition environment change, carried out continuous reform of the marketing system with “one center and four basic points” as the core, widely introduced academic marketing talents, further strengthened academic promotion and strengthened brand construction, Continue to build a marketing network and team to adapt to future market changes. The terminals covered by the company’s products include 12765 grade hospitals, 13273 chain pharmacies and monomer pharmacies, as well as 23645 grass-roots communities, health centers and clinics.
The whole terminal and whole mode marketing system is one of the important core competitiveness of the company.
The company continued to deepen the marketing reform. All kinds of sales models focused on end customers, realized the “pit system”, and consistently implemented the specific requirements of “one center and four basic points” for a long time, that is, taking customer hierarchical management as the center, and improving sales skills, product knowledge, academic ability and development ability as the four basic points.
(II) main products
At present, the company has 162 drug approval numbers, including 15 exclusive products. The company’s products with drug approval number include 29 drugs for cardiovascular and cerebrovascular system and nervous system, 13 drugs for musculoskeletal system, 19 drugs for urogenital system and sex hormones, 38 drugs for respiratory system and 44 drugs for digestive system and metabolism. Among them, 93 products have entered the national catalogue of drugs for basic medical insurance, industrial injury insurance and maternity insurance (2021 Edition), wohua ® Xinkeshu tablets were adjusted from medical insurance class B to class A, and 43 products entered the national catalogue of essential drugs (2018 Edition).
1. Exclusive products
The company has 15 exclusive products. The details are as follows:
List of exclusive products of the company
Serial number product name manufacturer Rx / OTC basic medicine medical insurance treatment field main functional traditional Chinese medicine category traditional Chinese medicine category
1 wohua ® Xinkeshu tablet Shandong Wohua Pharmaceutical Co.Ltd(002107) Rx is a drug therapy for cardiovascular diseases, removing blood stasis and promoting qi and blood circulation
2 is Gushukang capsule Liaoning wohuakangchen OTC a drug for osteoporosis of skeletal muscle system in the treatment of class a diseases of Bushen Zhuanggu agent
3 is Gushukang granule Liaoning wohuakangchen OTC a drug for osteoporosis of skeletal muscle system in the treatment of class a diseases of Bushen Zhuanggu agent
4 is Nanchang Jishun Rx Hedan tablet a lipid-lowering agent for the treatment of cardiovascular and cerebrovascular diseases
5 is Nanchang Jishun Rx Hedan capsule a lipid-lowering agent for the treatment of cardiovascular and cerebrovascular diseases
6 whether Naoxueshu oral liquid Shandong Wohua Pharmaceutical Co.Ltd(002107) Rx is a blood stasis removing agent for hemorrhagic stroke of cardiovascular and cerebrovascular diseases and a drug for promoting blood circulation and eliminating symptoms
7 shenzhiling oral liquid Shandong Wohua Pharmaceutical Co.Ltd(002107) RX no cardiovascular and cerebrovascular disease Alzheimer’s disease righting agent – tonifying Qi, supplementing qi and warming Yang agent
8 Tongluo Huatan capsule Shandong Wohua Pharmaceutical Co.Ltd(002107) RX no no no cardiovascular and cerebrovascular diseases ischemic stroke blood stasis removing agent blood stasis and phlegm removing agent
9 is amber Xiaoshi granule Shandong Wohua Pharmaceutical Co.Ltd(002107) RX a urinary system disease? Urinary system stone heat clearing agent Tonglin Xiaoshi agent is used for treatment
10 pediatric antipyretic granule Shandong Wohua Pharmaceutical Co.Ltd(002107) OTC no no pediatric medication upper respiratory tract infection surface relieving agent Xinliang surface relieving agent class a treatment
11. Yuandu Hanbi liquid Shandong Wohua Pharmaceutical Co.Ltd(002107) RX no no no skeletal muscle system anti rheumatism treatment of dampness dispelling agent and cold dehumidifier disease medication
12 Yuandu Hanbi medicinal liquor Shandong Wohua Pharmaceutical Co.Ltd(002107) RX no no no skeletal muscle system anti rheumatism treatment of dampness dispelling agent and cold dehumidifier disease medication
Fangshen Zhiyang granule Liaoning wohua Kangchen RX no no skin disease medication urticaria treatment dermatology medication dermatology medication
14 kudancao capsule Liaoning wohua Kangchen RX no digestion, gynecological diseases jaundice, bring down and other antipyretic agents – Qingzang Qinggan Dan antipyretic agents for the treatment of abdominal fever
15 Siyu Yangxue Yishen granule Liaoning wohua Kangchen OTC no no gynecological drugs to alleviate menopause Fuzheng agent Yangxue agent
Granular class A
2. Classification of main products
The company has 29 cardiovascular and cerebrovascular system and nervous system drugs. Among them, wohua ® Xinkeshu tablet, Hedan tablet / capsule, Naoxueshu oral liquid, Tongluo Huatan capsule and shenzhiling oral liquid are exclusive patented products in China. These varieties face hospitals, departments and hospitals
